Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma

Molecular Cancer Therapeutics

Volumn 9, Issue 3, 2010, Pages 535-544

  Kobayashi, Eisuke ^a,d   Masuda, Mari ^a   Nakayama, Robert ^b,d   Ichikawa, Hitoshi ^b   Satow, Reiko ^a   Shitashige, Miki ^a   Honda, Kazufumi ^a   Yamaguchi, Umio ^a   Shoji, Ayako ^e   Tochigi, Naobumi ^c   Morioka, Hideo ^d   Toyama, Yoshiaki ^d   Hirohashi, Setsuo ^a   Kawai, Akira ^a   Yamada, Tesshi ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b Genetics Division   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d KEIO UNIVERSITY   (Japan)

^e Mitsui Knowledge Industry Co   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ARGININE DEIMINASE; ARGININOSUCCINATE SYNTHASE; BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CXCR4; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EZRIN; FAS ANTIGEN; GELATINASE A; GELATINASE B; IFOSFAMIDE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; NONESSENTIAL AMINO ACID; PROTEIN P53; SURVIVIN; VASCULOTROPIN; WT1 PROTEIN;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; ARTICLE; AUXOTROPHY; CANCER ADJUVANT THERAPY; CANCER SURGERY; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CHILD; COHORT ANALYSIS; CULTURE MEDIUM; DNA MICROARRAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; OSTEOSARCOMA CELL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCHOOL CHILD;

ADOLESCENT; ADULT; ARGININOSUCCINATE SYNTHASE; BONE NEOPLASMS; CHILD; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOSARCOMA; PROGNOSIS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77949735952     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0774     Document Type: Article

References (41)

1. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776-90.
2. Meyers PA, Gorlick R, Heller G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 1998;16:2452-8.
3. Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest 2001;19:292-315.
4. Carsi B, Rock MG. Primary osteosarcoma in adults older than 40 years. Clin Orthop 2002:53-61.
5. Baldini N, Scotlandi K, Barbanti-Brodano G, et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 1995;333:1380-5.
6. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004;10:182-6.
7. Kaya M, Wada T, Akatsuka T, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 2000;6:572-7.
8. Tsunemi T, Nagoya S, Kaya M, et al. Postoperative progression of pulmonary metastasis in osteosarcoma. Clin Orthop 2003:159-66.
9. Foukas AF, Deshmukh NS, Grimer RJ, Mangham DC, Mangos EG, Taylor S. Stage-IIB osteosarcomas around the knee. A study of MMP-9 in surviving tumour cells. J Bone Joint Surg Br 2002;84:706-11.
10. Laverdiere C, Hoang BH, Yang R, et al. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res 2005;11:2561-7.
11. Clark JC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 2008;134:281-97.
12. Man TK, Chintagumpala M, Visvanathan J, et al. Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res 2005;65:8142-50.
13. Yamaguchi U, Nakayama R, Honda K, et al. Distinct gene expression-defined classes of gastrointestinal stromal tumor. J Clin Oncol 2008;26:4100-8.
14. Huang L, Shitashige M, Satow R, et al. Functional interaction of DNA topoisomerase IIα with the β-catenin and T-cell factor-4 complex. Gastroenterology 2007;133:1569-78.
15. Nitori N, Ino Y, Nakanishi Y, et al. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin Cancer Res 2005;11:2531-9.
16. Shitashige M, Satow R, Honda K, Ono M, Hirohashi S, Yamada T. Regulation of Wnt signaling by the nuclear pore complex. Gastroenterology 2008;134:1961-71, 71 e1-4.
17. Idogawa M, Masutani M, Shitashige M, et al. Ku70 and poly(ADP-ribose) polymerase-1 competitively regulate β-catenin and T-cell factor-4-mediated gene transactivation: possible linkage of DNA damage recognition and Wnt signaling. Cancer Res 2007;67:911-8.
18. Park YB, Kim HS, Oh JH, Lee SH. The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma. Int Orthop 2001;24:307-10.
19. Zhou H, Randall RL, Brothman AR, Maxwell T, Coffin CM, Goldsby RE. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol 2003;25:27-32.
20. Osaka E, Suzuki T, Osaka S, et al. Survivin as a prognostic factor for osteosarcoma patients. Acta Histochem Cytochem 2006;39:95-100.
21. Srivastava A, Fuchs B, Zhang K, et al. High WT1 expression is associated with very poor survival of patients with osteogenic sarcoma metastasis. Clin Cancer Res 2006;12:4237-43.
22. Hoang BH, Kubo T, Healey JH, et al. Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 2004;109:106-11.
23. Lafleur EA, Koshkina NV, Stewart J, et al. Increased Fas expression reduces the metastatic potential of human osteosarcoma cells. Clin Cancer Res 2004;10:8114-9.
24. Wu G, Morris SM, Jr. Arginine metabolism: nitric oxide and beyond. Biochem J 1998;336:1-17.
25. Husson A, Brasse-Lagnel C, Fairand A, Renouf S, Lavoinne A. Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle. Eur J Biochem 2003;270:1887-99.
26. Dillon BJ, Prieto VG, Curley SA, et al. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer 2004;100:826-33.
27. Lagarde SM, Ver Loren van Themaat PE, Moerland PD, et al. Analysis of gene expression identifies differentially expressed genes and pathways associated with lymphatic dissemination in patients with adenocarcinoma of the esophagus. Ann Surg Oncol 2008;15:3459-70.
28. Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res 2002;62:5443-50.
29. Wheatley DN, Campbell E. Arginine deprivation, growth inhibition and tumour cell death: 3. Deficient utilisation of citrulline by malignant cells. Br J Cancer 2003;89:573-6.
30. Yoon CY, Shim YJ, Kim EH, et al. Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. Int J Cancer 2007;120:897-905.
31. Szlosarek PW, Klabatsa A, Pallaska A, et al. In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res 2006;12:7126-31.
32. Bowles TL, Kim R, Galante J, et al. Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase. Int J Cancer 2008;123:1950-5.
33. Kim JH, Yu YS, Kim DH, Min BH, Kim KW. Anti-tumor activity of arginine deiminase via arginine deprivation in retinoblastoma. Oncol Rep 2007;18:1373-7.
34. Ascierto PA, Scala S, Castello G, et al. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 2005;23:7660-8.
35. Izzo F, Marra P, Beneduce G, et al. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol 2004;22:1815-22.
36. Shen LJ, Lin WC, Beloussow K, Shen WC. Resistance to the antiproliferative activity of recombinant arginine deiminase in cell culture correlates with the endogenous enzyme, argininosuccinate synthetase. Cancer Lett 2003;191:165-70.
37. Gong H, Zolzer F, von Recklinghausen G, et al. Arginine deiminase inhibits cell proliferation by arresting cell cycle and inducing apoptosis. Biochem Biophys Res Commun 1999;261:10-4.
38. Gong H, Zolzer F, von Recklinghausen G, Havers W, Schweigerer L. Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis. Leukemia 2000;14:826-9.
39. Beloussow K, Wang L, Wu J, Ann D, Shen WC. Recombinant arginine deiminase as a potential anti-angiogenic agent. Cancer Lett 2002;183:155-62.
40. Park IS, Kang SW, Shin YJ, et al. Arginine deiminase: a potential inhibitor of angiogenesis and tumour growth. Br J Cancer 2003;89:907-14.
41. Gong H, Pottgen C, Stuben G, Havers W, Stuschke M, Schweigerer L. Arginine deiminase and other antiangiogenic agents inhibit unfavorable neuroblastoma growth: potentiation by irradiation. Int J Cancer 2003;106:723-8.